AZIENDA OSPEDALE UNIVERSITA PADOVA

Their core work

Azienda Ospedale Università Padova is the university hospital of Padova, one of Italy's leading academic medical centers. Their H2020 work concentrates on liver disease research — from cirrhosis screening and treatment to pediatric liver tumors — alongside contributions to sickle cell disease, autoimmune disorders, and regenerative medicine for heart valves. They bring clinical trial infrastructure and patient cohort access to European research consortia, serving as a clinical validation site rather than a basic research lab.

What they specialise in

How they've shifted over time

Early H2020 work (2015–2017) was split between cardiovascular tissue engineering (heart valve replacement via decellularization) and initial involvement in liver disease research (NAFLD, nanoporous carbon therapies). From 2019 onward, the hospital concentrated heavily on chronic disease stratification — autoimmune disease trajectories, predictive modeling for treatment response, and population-level liver screening. The shift suggests a move from interventional/surgical research toward data-driven disease understanding and public health implementation.

Moving toward precision medicine approaches and population-level screening, making them a strong partner for projects combining clinical data with predictive analytics.

How they like to work

AOUP has never coordinated an H2020 project — they consistently join as a participant or third party, contributing clinical expertise and patient access to large consortia. With 168 unique partners across 27 countries, they operate in broad, multinational networks rather than tight recurring clusters. This profile points to an organization valued for its clinical infrastructure and patient cohorts rather than project leadership, making them a reliable but hands-off consortium member.

Connected to 168 unique partners across 27 countries, indicating wide but non-repeated collaboration. Their network spans virtually all of Europe plus African partnerships through the sickle cell ARISE project.

What sets them apart

As a major Italian university hospital, AOUP offers what pure research institutes cannot: direct access to patient populations, clinical trial infrastructure, and real-world validation environments. Their deep concentration in liver disease — four separate projects covering different stages from screening to decompensated cirrhosis — gives them unusual depth in a specific therapeutic area. For consortium builders, they are a credible clinical partner who can deliver patient recruitment and endpoint data in hepatology and increasingly in autoimmune disease.

Highlights from their portfolio

• 3TR
  Largest funded project (EUR 277,004) tackling treatment non-response across autoimmune diseases using integrative genomics and predictive modeling — signals their move into precision medicine.
• LiverScreen
  Population-based liver fibrosis screening study across multiple European countries, combining clinical validation with health economics and implementation strategy.
• ARISE (2015)
  Their highest single funding (EUR 310,300) for individualized heart valve regeneration using decellularization — their only project outside internal medicine.